Sat, Dec 27, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Saemor Capital fund returns 9.3% in H1, complies with AIFMD

Friday, July 25, 2014

Komfie Manalo, Opalesque Asia:

Quantitative investment management specialist Saemor Capital B.V., reported that its Saemor Capital Europe Alpha Fund returned 9.3% in the first half of 2014 (+6.5% in June), the highest in the equity market neutral and quantitative group categories.

Saemor Capital’s Founder and CEO Sven Bouman said a pro-risk approach at the start of the year and subsequently a more cautious portfolio stance have worked out well.

"The long as well as the short book of the fund performed well. Almost every sector made a positive contribution. On a stock level, long positions Actelion, Pandora, Enel, Statoil and Yara were instrumental. Several short positions also added to the performance as their share prices came under pressure after issuing a profit warning," he said.

Bouman continued, "Our quantitative stock selection model posted very solid returns. We look at roughly 50 factors in four quadrants: valuation, momentum, profitability & growth and quality. For the year almost all the factors we look at are in black with earnings revisions being the standout performer. Value factors are second-to-best. Early in the year investors were buying stocks with low cyclical valuation like price-to-book. Subsequently the more defensive value factors started to do well as economic data started to come in below expectations. As a result high dividend stocks came back in favor, helped by the low interest rate ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its